高级检索
当前位置: 首页 > 详情页

In vitro effect of mPE(2k)-PCLx micelles on rat liver cytochrome P450 enzymes

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Dept Pharmaceut, 13 Hongkong Rd, Wuhan 430030, Hubei, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Tongji Hosp, Dept Pharm, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China
出处:
ISSN:

关键词: mPEG(2k)-PCLx micelles Cytochrome P450 enzymes Inhibition Induction Rat liver microsomes Primary rat hepatocytes

摘要:
The present study was aimed to evaluate the effects of amphiphilic copolymer micelles on six major hepatic cytochrome P450 (CYP) isoforms. A series of mPE(2k)-PCLx polymeric micelles (mPE(2k)-PCL2k, mPE(2k)-PCL3-5k, mPE(2k)-PCL5k and mPE(2k)-PCL10k) ranging from 20 to 100 nm were prepared to investigate the inhibitory or inductive activities by in vitro incubations of rat liver microsomes and primary rat hepatocytes. Inhibition of these polymeric micelles on CYP1A2, CYP2B1, CYP2C6, CYP2C11, CYP2D2 and CYP3A1/2 isoenzymes were observed above their critical micelle concentrations (> 10 mu g.mL(-1)) and in a concentration-dependent manner. The mPE(2k)-PCL(2k )micelles showed the strongest inhibition of CYP1A2, followed by CYP2C11. The micelles with lower molecular weight PCL segment exhibited more potent inhibitory potential. Induction on CYP1A2, CYP2B1 and CYP3A1/2 activity (2.1-7.2-fold, 1.5-2.4-fold and 1.3-3.0-fold, respectively) were detected at all tested concentrations (0.1-1000 mu g.mL(-1) or 0.1-100 mu g.mL(-1)). Accordingly, most of the mRNA levels were upregulated. As demonstrated in ex vivo fluorescence imaging results, the mPE(2k)-PCLx micelles mainly accumulated in the liver after intravenous administration. In conclusion, mPE(2k)-PCLx micelles can interfere with the normal metabolic function of CYP450s in vitro, indicating polymeric micelles as promising drug nano-carriers might cause micelle-drug interaction and the in vivo interaction deserves further investigation.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学
JCR分区:
出版当年[2016]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Dept Pharmaceut, 13 Hongkong Rd, Wuhan 430030, Hubei, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:2 总访问量:412 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)